Comparison of efficacy and safety of Drotaverine Versus Mebeverine in Irritable Bowel Syndrome

Phase 4

Completed

• Conditions: Health Condition 1: null- Irritable Bowel Syndrome

• Registration Number: CTRI/2017/11/010529
• Lead Sponsor: Walter Bushnell Pvt Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-11-30
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

Patients between 18 to 80 years of either gender

Fulfillment of IBS Rome III criteria

Written informed consent

Exclusion Criteria

Failure to meet all inclusion criteria

Pregnant females

Patients with comorbid diseases, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF)

Patients taking drugs which modify or aggravate symptoms (antidepressants, calcium channel blockers etc)

Patients having hypothyroidism & gluten hypersensitivity

Any history of fever, passage of blood in stool, loss of weight, any organic disease of GI tract in the recent past

Patients on any other concomitant medication for abdominal pain, bowel disturbance or altering gastrointestinal motility

Malignancy of any other organ

Study & Design

• Study Type: Interventional
• Study Design: Not specified